- Alternative Medicine
- Mesothelioma Cure
- Mesothelioma Research
- Mesothelioma Doctors
- Mesothelioma Cancer Centers
- Mesothelioma Clinical Trials
Over 30 Billion dollars in trust fund money has been set aside for asbestos victims.
Get a Free copy of Surviving Mesothelioma, Lean on Me, or 100 Questions & Answers About Mesothelioma
Mesolink.org now offeres Free Assistance with VA Claims and other benefits.
Dr. Jack A Elias
One of the foremost researchers and clinicians for the treatment of mesothelioma, Dr. Jack A. Elias, M.D. currently leads the Department of Internal Medicine at Yale School of Medicine, serving as Chairman. He also functions as Waldemar Von Zedtwitz Professor of Medicine Chief of the Beeson Medical Service at Yale-New Haven Hospital. Many educators, clinicians, and investigators from around the world comprise the Internal Medicine department at Yale. Boasting 600 volunteer faculty members, as well as approximately 35 regular faculty members, the department also trains approximately 430 residents.
After graduating from the University of Pennsylvania School of Medicine, Elias completed residencies at the Hospital of the University of Pennsylvania (HUP) and Tufts-New England Medical Center in Boston. He then completed fellowships in allergy and immunology, and in pulmonary and critical care Medicine at HUP.
Dr. Elias has written and co-written a number of articles published in peer-reviewed journals, as well as textbook chapters. The articles include "Interleukin-13 induces tissue fibrosis by selectively stimulating and activating TGF-§1," published in the Journal of Experimental Medicine, which has important implications regarding pathogenesis of toxin-related lung damage. He also co-wrote "Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase- and cathepsin-dependent emphysema" and "Adenosine is an important mediator of IL-13 induced inflammation in the lung: Evidence for anIL-13-adenosine amplification pathway," both published in the Journal of Clinical Investigation. Other articles have appeared in the Journal of Immunology, the Journal of Biological Chemistry, the Journal of Allergy and Clinical Immunology, and the American Journal of Respiratory Cellular Molecular Biology. He is also the author of the Fishman's Manual of Pulmonary Diseases and Disorders.
Dr. Elias has received a number of honors, including the Recognition Award for Scientific Accomplishment awarded by the American Thoracic Society. He has without fail received research funding from the National Institutes of Health since 1984, serving as the Principal Investigator on a Program Project grant. He has also received four National Institutes of Health RO1 grants and a T32 training grant in Pulmonary Biology. Dr. Elias been honored with multiple commercial research awards for major advances in various laboratory methods and areas of research. Many of his findings have yielded patents and several collaborative projects between Yale and pharmaceutical companies in the development of new pulmonary drugs. As a noted authority on lung injury, inflammation and repair, Dr. Elias was the first to translate laboratory models of respiratory pathogenic mechanisms to human pulmonary diseases.
Dr. Elias’ clinical research interests include chronic obstructive pulmonary disease (COPD), asthma, acute lung trauma, and interstitial lung disease, a scarring of the lungs that has been linked to inhalation of occupational toxins or asbestos fibers. Elias has engaged in research in a variety of areas, including asthma, emphysema, lung injuries, transgenic models of lung disease, and the effector mechanisms of various chemical messengers in the lung.